Rhode Island Biotechnology Company EpiVax, Inc. Receives $ 368K Federal Grant to Reengineer Botulinum Toxin Using ''Immunoinformatics''

Published: Feb 28, 2007

PROVIDENCE, R.I.--(BUSINESS WIRE)--EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has received a grant to reengineer botulinum toxin, a protein that is used for cosmetic purposes (the most commonly used brand is known as “Botox”) and which is also used as a revolutionary therapeutic for movement disorders categorized as “dystonias” such as Parkinson’s Disease and Cerebral Palsy.

Back to news